Redhill Biopharma Ltd (RDHL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has a cash flow conversion efficiency ratio of 0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.51 Million) by net assets ($-4.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RDHL net asset quality index to measure how much of total assets are equity-financed.
Redhill Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Redhill Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RDHL cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Redhill Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Redhill Biopharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OZZ Resources Ltd
AU:OZZ
|
0.105x |
|
KWESST Micro Systems Inc. Common Stock
NASDAQ:KWE
|
-0.237x |
|
Guard Therapeutics International AB
ST:GUARD
|
-1.630x |
|
Kumho Industrial Co Ltd
KO:002995
|
0.632x |
|
Searchlight Resources Inc
V:SCLT
|
-0.141x |
|
Health and Plant Protein Group Ltd
AU:HPP
|
-0.067x |
|
Group 107 Ltd
TA:G107
|
-0.133x |
|
Madhav Marbles and Granites Limited
NSE:MADHAV
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Redhill Biopharma Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Redhill Biopharma Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.27 Million | $-9.65 Million | -2.261x | -213.03% |
| 2024-12-31 | $-4.68 Million | $-9.37 Million | 2.001x | +111.56% |
| 2023-12-31 | $2.07 Million | $-35.82 Million | -17.313x | -2971.10% |
| 2022-12-31 | $-48.40 Million | $-29.18 Million | 0.603x | +108.23% |
| 2021-12-31 | $8.88 Million | $-65.05 Million | -7.329x | -109.17% |
| 2020-12-31 | $13.86 Million | $-48.58 Million | -3.504x | -415.95% |
| 2019-12-31 | $60.00 Million | $-40.75 Million | -0.679x | -0.87% |
| 2018-12-31 | $51.19 Million | $-34.46 Million | -0.673x | +32.23% |
| 2017-12-31 | $45.06 Million | $-44.77 Million | -0.993x | -120.43% |
| 2016-12-31 | $62.70 Million | $-28.26 Million | -0.451x | -51.89% |
| 2015-12-31 | $60.08 Million | $-17.83 Million | -0.297x | +39.31% |
| 2014-12-31 | $25.01 Million | $-12.23 Million | -0.489x | +30.88% |
| 2013-12-31 | $11.93 Million | $-8.44 Million | -0.707x | -97.99% |
| 2012-12-31 | $19.02 Million | $-6.79 Million | -0.357x | -43.09% |
| 2011-12-31 | $18.79 Million | $-4.69 Million | -0.250x | -124.39% |
| 2010-12-31 | $-1.59 Million | $-1.63 Million | 1.024x | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more